🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Switzerland / NCT07792811
Starting soon Phase 2/3

Non-Invasive Deep Brain Stimulation for Upper Limb Recovery After Stroke (NIMBUS)

NCT07792811 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Friedhelm Hummel
Phase
Phase 2/3
Started
2026-09-13
Last updated
2026-08-28

Condition(s) studied

StrokeStroke Assessment

Investigational drug(s) / intervention(s)

Non-invasive transcranial Temporal Interference Stimulation (iTBS-tTIS Striatum)Concurrent Intensive Motor RehabilitationNon-invasive transcranial Temporal Interference Stimulation sham-tTIS Striatum)

Non-invasive transcranial Temporal Interference Stimulation (iTBS-tTIS Striatum): Transcranial Temporal Interference Stimulation (tTIS) is a non-invasive neuromodulation technique that applies multiple high-frequency electrical currents via scalp electrodes to generate an amplitude-modulated electric field in deep brain regions without surgery. The technique allows targeting of different deep brain structures depending on electrode configuration and current parameters. In this study, stimulation is individualized to target the striatum using subject-specific electrode placement based on anatomical information. The stimulation is delivered in a theta-burst-patterned protocol designed to induce plasticity-related effects. tTIS is applied concurrently with upper-limb rehabilitative training during each session. The intervention is administered over five consecutive days, with three sessions per day within an accelerated protocol.

Concurrent Intensive Motor Rehabilitation: Participants undergo intensive, task-oriented upper-limb rehabilitation training focused on improving motor function of the affected arm and hand following stroke. Training is delivered in a structured and personalized manner, adapted to the participant's level of impairment and functional capacity. Each session includes approximately 30 minutes of physiotherapy involving repetitive, goal-directed movements and functional tasks targeting upper-limb use. The rehabilitation is provided concurrently with stimulation (active or sham) and follows an accelerated schedule of three sessions per day over five consecutive days.

Non-invasive transcranial Temporal Interference Stimulation sham-tTIS Striatum): Sham Transcranial Temporal Interference Stimulation (tTIS) is a non-invasive neuromodulation procedure that applies two identical high-frequency electrical currents via scalp electrodes. Because the currents have the same frequency, no low-frequency amplitude-modulated electric field is generated in deep brain regions. The sham stimulation uses the same individualized electrode placement based on anatomical information and follows the same stimulation schedule and device settings as the active intervention, while not delivering the temporal interference pattern intended to modulate striatal activity. Sham tTIS is applied concurrently with upper-limb rehabilitative training during each session. The intervention is administered over five consecutive days, with three sessions per day within an accelerated protocol.

Study summary

NIMBUS is a clinical study evaluating a new, non-invasive brain stimulation treatment to improve arm and hand function in people with long-term effects of stroke. The treatment uses a personalized method to stimulate deeper areas of the brain through the scalp, without surgery, while participants undergo intensive physiotherapy rehabilitation. Physiotherapy in combination with the brain stimulation will occur three times a day over the course of a week. In the study, participants are randomly assigned to receive either the active treatment or a sham (inactive) version, so researchers can compare the outcomes fairly. The study will assess whether the treatment is safe, feasible, and effective by measuring changes in arm movement, daily activities, and brain function before and after the treatment. The goal is to determine whether this approach can enhance recovery after stroke and support the development of improved rehabilitation therapies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Informed Consent signed by the participant 2. Age ≥ 18 years old 3. First ever ischemic stroke with motor impairment 4. Stroke incident ≥ 12 weeks at consent 5. Moderate to severe motor impairment (Fugl-Meyer Assessment (FMA) \>20 and \<58) Exclusion Criteria: 1. Unable to provide informed consent due to cognitive, psychiatric, or medical conditions impairing decision-making capacity 2. Severe neuropsychiatric (e.g., major depression, schizophrenia) or medical disease (e.g., progressive cancer, unstable systemic disease, neurodegenerative disease) 3. Severe cognitive, sensory or musculoskeletal dysfunctions prohibiting to understand instructions or to perform the rehabilitative tasks 4. Contraindications for NIBS or MRI a. Electronic or ferromagnetic medical implants/device, non-MRI compatible metal implant, b. Fully or partially implanted conductive objects i. Passive implants: stents, orthopedic/orthodontic implants, screws, shunts, etc. ii. Active implants: cochlear implants, deep brain stimulation leads and electrodes, fully implanted brain monitoring devices iii. Partially implanted devices: monitoring electrodes (e.g., stereoelectroencephalography, electrocortigraphy, etc. iv. Surface-mounted conductive objects: conductive low-impedance structure mounted to the skin that may introduce shortcuts. c. History of seizures d. Medication that significantly interacts with NIBS being benzodiazepines, tricyclic antidepressants and antipsychotics. e. Non-intact skin where electrodes are intended ot be placed 5. Pregnancy 6. Regular use of narcotic drugs or abusive alcohol consumption 7. Integral and bilateral lesion of the striatum 8. Concomittant participation in another clinical trial 9. Active request of not being informed in case of incidental findings

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CRR SUVA Sion Valais

More Friedhelm Hummel trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07792811 on ClinicalTrials.gov ↗ ← All trials in Switzerland